Khiron Life Sciences Corp.
KHRNF · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $13 | $8 | $10 | $1 |
| % Growth | 59.6% | -16.3% | 974.6% | – |
| Cost of Goods Sold | $6 | $1 | $7 | $1 |
| Gross Profit | $6 | $7 | $2 | $0 |
| % Margin | 49.8% | 87.4% | 25.4% | 33.3% |
| R&D Expenses | $1 | $2 | $4 | $0 |
| G&A Expenses | $21 | $26 | $31 | $18 |
| SG&A Expenses | $24 | $28 | $36 | $20 |
| Sales & Mktg Exp. | $3 | $2 | $5 | $2 |
| Other Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Expenses | $26 | $31 | $40 | $20 |
| Operating Income | -$20 | -$24 | -$37 | -$20 |
| % Margin | -154.6% | -294.4% | -390.6% | -2,231.3% |
| Other Income/Exp. Net | -$14 | -$0 | $1 | -$1 |
| Pre-Tax Income | -$34 | -$24 | -$36 | -$20 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$33 | -$24 | -$36 | -$20 |
| % Margin | -258.9% | -299.8% | -379.6% | -2,221.3% |
| EPS | -0.2 | -0.2 | -0.36 | -0.41 |
| % Growth | 0% | 44.4% | 12.2% | – |
| EPS Diluted | -0.2 | -0.2 | -0.36 | -0.41 |
| Weighted Avg Shares Out | 165 | 120 | 102 | 48 |
| Weighted Avg Shares Out Dil | 165 | 120 | 102 | 49 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | -$32 | -$23 | -$36 | -$18 |
| % Margin | -250.4% | -285.1% | -380.8% | -2,050.9% |